(Q34376451)

1 August 2017

Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. (English)

1 reference

1 August 2017

1 reference

1 reference

Eric J Huang

4

0 references

Bruce A C Cree

series ordinal

5

object named as

Bruce A C Cree

1 reference

1 August 2017

Jeffrey M Gelfand

1

1 reference

1 August 2017

Jennifer Cotter

series ordinal

2

1 reference

1 August 2017

Jeffrey Klingman

series ordinal

3

1 reference

1 August 2017

language of work or name

1 reference

9 October 2014

1 reference

Neurology(R) neuroimmunology & neuroinflammation

1 August 2017

1 reference

1 August 2017

1

1 reference

1 August 2017

e34

1 reference

1 August 2017

3

1 reference

Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis

1 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204228

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204228

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204228

Neuromyelitis optica: diagnosis, pathogenesis, and treatment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204228

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204228

Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204228

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204228

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204228

Immunopathology of secondary-progressive multiple sclerosis.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204228

A secondary progressive clinical course is uncommon in neuromyelitis optica

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25340086

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A comparison of the pathology of primary and secondary progressive multiple sclerosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25340086

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1212/NXI.0000000000000034

1 reference

1 August 2017

1 reference

1 August 2017

1 reference